AbbVie (ABBV) Share-based Compensation (2012 - 2026)

AbbVie (ABBV) has reported Share-based Compensation for 15 consecutive years, with $166.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 7.26% year-over-year to $166.0 million in Q2 2026; TTM through Jun 2026 was $976.0 million, a 4.5% increase from a year earlier, with the FY2025 full-year figure at $955.0 million, up 4.83% from the prior year.
• Share-based Compensation was $166.0 million for Q2 2026 at AbbVie, down from $444.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $444.0 million in Q1 2026 and troughed at $107.0 million in Q2 2022.
• A 5-year average of $216.3 million and a median of $179.0 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 32.7% in 2022 and surged 67.29% in 2023, its largest moves.
• Over 5 years, Share-based Compensation stood at $132.0 million in 2022, then fell by 5.3% to $125.0 million in 2023, then surged by 31.2% to $164.0 million in 2024, then dropped by 4.27% to $157.0 million in 2025, then gained by 5.73% to $166.0 million in 2026.
• The last three Share-based Compensation figures came in at $166.0 million (Q2 2026), $444.0 million (Q1 2026), and $157.0 million (Q4 2025), per Business Quant data.